Cooperative, nanoparticle-enabled thermal therapy of breast cancer.
Cooperative, nanoparticle-enabled thermal therapy of breast cancer.
复制标题
DOI：
10.1002/adhm.201100005
复制
发表时间：
2012-01-11
影响因子：
10
通讯作者：
Ferrari, Mauro
中科院分区：
文献类型：
--
作者：
Shen, Haifa;You, Jian;Zhang, Guodong;Ziemys, Arturas;Li, Qingpo;Bai, Litao;Deng, Xiaoyong;Erm, Donald R.;Liu, Xuewu;Li, Chun;Ferrari, Mauro
尽管数十年来致力于癌症治疗的研究和药物开发，癌症仍然是世界上人类死亡的主要原因之一[1]。人类癌症由携带多种基因突变的恶性细胞混合群组成。据估计，胶质母细胞瘤 [2] 或胰腺癌 [3] 的单个肿瘤中约有 40 个 DNA 突变导致氨基酸变化，而乳腺癌和结直肠癌中的突变数量是其两倍 [4]。其中许多是决定肿瘤发生、进展和转移的驱动突变。基因组图谱表明，多种信号转导途径决定癌细胞的命运，用单一治疗剂治疗癌症几乎是不可能的。因此，毫不奇怪的是，许多最近开发的靶向治疗药物，例如用于非小细胞肺癌治疗的 EGFR 抑制剂和用于乳腺癌治疗的赫赛汀，仅对某些癌症患者有效 [5, 6]；在许多情况下，耐药性是由额外的遗传和表观遗传改变引起的。据报道，EGFR基因[7, 8]、KRAS基因[9, 10]内的突变以及其他信号通路的上调[11, 12]都可能导致EGFR靶向治疗产生耐药性。显然，在对抗这种致命疾病的斗争中，开发独立于癌症遗传背景的新疗法有着紧迫而持久的动机。纳米技术在癌症疗法的发展中发挥了至关重要的作用[13]。 Doxil™ 和 Abraxane™[14-17] 只是纳米制剂药物的两个例子。目前正在探索金纳米粒子诱导高温细胞毒性[18-22]。当暴露在正确波长的光下时，纳米颗粒的导带电子会产生热量，并传递到细胞和周围组织。热疗法的优点是可以杀死癌细胞，且不产生耐药性，无论遗传背景如何，因此可以适用于所有癌症患者。然而，这种方法的成功应用需要金纳米粒子在肿瘤中足够的积累以及激发能量足够的肿瘤穿透性[23]。由于缺乏有效的递送，大多数研究中金纳米颗粒的肿瘤递送一直依赖于增强的
Despite decades of effort on research and drug development for cancer treatment, cancer still remains one of the major causes of human deaths in the world [1]. Human cancers consist of mixed population of malignant cells that carry multiple genetic mutations. It has been estimated that there are around 40 DNA mutations that result in amino acid changes in an individual tumor of glioblastoma [2] or pancreatic cancer [3], and twice as many mutations in breast and colorectal cancers [4]. Many of them are driver mutations that determine tumor initiation, progression and metastasis. The genomic landscapes indicate that multiple signal transduction pathways determine the fate of a cancer cell, and it is almost impossible to treat cancer with a single therapeutic agent. It is thus not surprising that many of the recently developed targeted therapy drugs, such as the EGFR inhibitors for non-small-cell lung cancer treatment and Herceptin for breast cancer therapy, are effective in only a certain set of cancer patients [5, 6]; and in many cases, drug resistance arises from additional genetic and epigenetic alterations. It has been reported that mutations within the EGFR gene [7, 8], the KRAS gene [9, 10], and up-regulation of other signaling pathways [11, 12] could all cause resistance to EGFR-targeted therapy. Clearly, there is an urgent and persistent motivation to develop novel therapeutics independent of cancer genetic background in the fight against this deadly disease.Nanotechnology has played a crucial role in the development of cancer therapeutics [13]. Doxil™ and Abraxane™[14–17] are just two examples of nanoformulated drugs. Gold nanoparticles are currently being explored to induce hyperthermic cytotoxicity [18–22]. When exposed to light at the right wavelength, the conduction-band electrons of the nanoparticle generate heat that is transmitted to the cells and surrounding tissues. Thermal therapy has the advantage of killing cancer cells without causing resistance regardless of genetic background, and thus can be applied to all cancer patients. However, successful application of this approach requires adequate accumulation of gold nanoparticles in the tumor and sufficient tumor penetration of the excitation energy [23]. Due to lack of effective delivery, tumor delivery of gold nanoparticles in most studies has been relied on the enhanced
登录
查看更多内容
影响因子：
158.5
作者：
Lynch, TJ;Bell, DW;Haber, DA
通讯作者：
Haber, DA
影响因子：
45.3
作者：
Eberhard, DA;Johnson, BE;Hillan, KJ
通讯作者：
Hillan, KJ
DOI：
10.1073/pnas.2232479100
发表时间：
2003-11-11
影响因子：
11.1
作者：
Hirsch, LR;Stafford, RJ;West, JL
通讯作者：
West, JL
影响因子：
14
作者：
Decuzzi, Paolo;Ferrari, Mauro
通讯作者：
Ferrari, Mauro
影响因子：
158.5
作者：
Kobayashi, S;Boggon, TJ;Halmos, B
通讯作者：
Halmos, B